March 23, 2021
Taisho Pharmaceutical said on March 22 that it has submitted a new drug application in Japan for ozoralizumab, an anti-TNFα nanobody licensed from Belgium-based Ablynx, for the treatment of rheumatoid arthritis (RA) inadequately controlled with existing therapies. The submission is...read more